Vis enkel innførsel

dc.contributor.authorLundberg, Helge Einar
dc.contributor.authorHolo, Helge
dc.contributor.authorHoland, Trond
dc.contributor.authorFagertun, Hans E.
dc.contributor.authorLarsen, Stig
dc.date.accessioned2021-12-02T11:36:56Z
dc.date.available2021-12-02T11:36:56Z
dc.date.created2021-11-30T13:37:27Z
dc.date.issued2021
dc.identifier.citationInternational Journal of Clinical Trials. 2021, 8 (3), 174-183.
dc.identifier.issn2349-3240
dc.identifier.urihttps://hdl.handle.net/11250/2832553
dc.description.abstractBackground: Daily maximum effective dose (MED) of Jarlsberg® increased the serum osteocalcin (tOC) level, vitamin K2 and affected the lipid pattern positively. The aim of the study was to estimate and verify a daily maintenance dose. Methods: 12 healthy female volunteers (HV) were included in a de-escalation study after a six week run-in period on the daily MED of 57 g Jarlsberg® cheese. A 3-level within-patient response surface pathway (RSP) design with individual starting values was developed. Another 12 HVs were included in a new study with a six week run-in period on MED followed with six weeks on the estimated maintenance dose. All HVs were premenopausal female between 20 and 52 years of age. The main variable in the studies was the tOC level. Results: tOC, cOC and the vitamin K2 variants increases significantly (p<0.01) during the run-in period on daily MED of Jarlsberg® in both studies. The maintenance daily dose was estimated to 45 g (95% CI: 38-52 g/day) and used in the new study. The tOC level was reduced from 19.8 ng/ml (95% CI: 12.0-27.6) obtained in the run-in period to 18.5 ng/ml (95% CI: 11.7-25.3) during the maintenance part. This represents a reduction of 6.6%. The sum of vitamin K2 variants changed from 0.58 ng/ml on MED of Jarlsberg® to 0.59 ng/ml (95% CI: 0.37-0.82) during the maintenance period. Conclusions: Daily MED of Jarlsberg® cheese increases tOC, cOC and the vitamin K2 level. The maintenance Jarlsberg® dose was estimated to 45 g/day and verified as sufficient.
dc.language.isoeng
dc.relation.urihttps://www.ijclinicaltrials.com/index.php/ijct/article/view/506/283
dc.subjectBeinhelse
dc.subjectBone health
dc.subjectLipidsenkende legemidler
dc.subjectLipid lowering drugs
dc.titleDetermination of maintenance Jarlsberg® cheese dose to keep the obtained serum osteocalcin level; a response surface pathway designed de-escalation dose study with individual starting values
dc.typeJournal article
dc.description.versionpublishedVersion
dc.subject.nsiVDP::Forebyggende medisin: 804
dc.subject.nsiVDP::Preventive medicine: 804
dc.source.pagenumber174-183
dc.source.volume8
dc.source.journalInternational Journal of Clinical Trials
dc.source.issue3
dc.identifier.doi10.18203/2349-3259.ijct20212841
dc.identifier.cristin1961743
dc.relation.projectTINE SA: 310059
dc.relation.projectNorges forskningsråd: 310059
cristin.ispublishedtrue
cristin.fulltextoriginal


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel